Sun Pharma to sell two divisions to Strides

Chennai, Sep 19 (IANS) Indian drug major Sun Pharmaceutical Industries Ltd will sell its two divisions operating in the central nervous system (CNS) segment to Strides Arcolab Ltd for Rs.165 crore.

In a statement issued jointly with Strides, Sun Pharma said the two have entered into a definitive agreement related to Solus and Solus Care divisions of erstwhile Ranbaxy.

According to the statement, Sun Pharma will transfer the two marketing divisions along with the employees to Strides.

The two divisions have been accounting for a revenue of Rs.92 crore.

Commenting on the transaction, Abhay Gandhi, CEO – India Business, Sun Pharma said: “The agreement with Strides is part of our strategy to firmly consolidate our CNS business in India.”

According to him, post successful completion of Ranbaxy’s merger the company had an opportunity to assess the entire portfolio of its India business.

“We have evaluated each and every therapy segment that we are present in and how these businesses can grow going forward. Based on this evaluation, we firmly believe that the potential of Solus and Solus Care divisions can be greatly enhanced with the focus that Strides will put in growing them,” he was quoted as saying in the statement.

According to Subroto Banerjee, president-Brands, India of Strides, the acquisition of the two divisions will enable growth of the company’s branded business in India.

The transaction is subject to approval from the Competition Commission of India and other customary closing conditions. All other terms and conditions of the transaction are confidential, the two companies said.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of or any employee thereof. is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here